Chemotherapy News and Research

Latest Chemotherapy News and Research

Scientists win awards for the discovery of genomic imprinting and tumor’s power grid

For their discovery of genomic imprinting, developmental biologists Davor Solter and Azim Surani will receive the 2026 Paul Ehrlich and Ludwig Darmstaedter Prize, endowed with €120,000, on March 14 at Frankfurt’s Paulskirche.

13 Mar 2026

Defining the limits of immunotherapy in early small-cell lung cancer

Immunotherapy given during and after chemoradiation did not improve survival for study participants with limited-stage, small-cell lung cancer (SCLC) according to the results of an international clinical trial, NRG-LU005, led by NRG Oncology in collaboration with the Alliance for Clinical Trials in Oncology. The results are published in the Journal of Clinical Oncology.

13 Mar 2026

Topical cream activates immune response to suppress skin cancer growth

A topical cream activated the skin's immune defenses and suppressed tumor growth in two preclinical models of cutaneous squamous cell carcinoma (cSCC), one of the most common cancers in the world, according to a study published today in the Journal of Clinical Investigation.

12 Mar 2026

Romiplostim prevents chemotherapy-induced thrombocytopenia in phase 3 trial

Results from a global phase 3 clinical trial led by investigators at Mass General Brigham show that the medication romiplostim can effectively prevent chemotherapy from destroying platelet-producing bone marrow cells, a common complication known as chemotherapy-induced thrombocytopenia.

12 Mar 2026

Structured exercise helps chemotherapy patients maintain cognitive function and mental clarity

New research in the March 2026 issue of JNCCN-Journal of the National Comprehensive Cancer Network suggests that exercise may help people with cancer stay mentally sharp and better able to handle daily tasks, work, and social activities through chemotherapy treatment delivered on an every two-week cycle.

12 Mar 2026

Combat Medical raises £2.6 million Series A to advance treatment of BCG unresponsive bladder cancer

Combat Medical (Combat), a medical device company optimizing the delivery and efficacy of cancer therapeutics, today announced it has raised £2.6 million in the first close of a Series A financing to advance its hyperthermic intravesical chemotherapy treatment, HIVEC® through phase 3 clinical trials and toward FDA registration.

From Combat Medical 12 Mar 2026

New protein target for safer lung cancer therapy

Researchers at the University of Gothenburg have identified a protein linked to an increased risk of metastasis and recurrence in lung cancer. The findings are presented in a study that paves the way for new precision medicine approaches, particularly for older patients.

12 Mar 2026

New consensus defines oligometastatic stage in pancreatic cancer

Until now, the following has been true for metastatic pancreatic cancer: Once the tumor has spread, local treatment such as surgery is usually no longer an option.

10 Mar 2026

Depleting a clotting protein fibrinogen could slow down pancreatic cancer

Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have found that depleting a clotting protein made by the liver could slow down pancreatic cancer.

10 Mar 2026

FOXJ1 gene may drive resistance to taxane chemotherapy in advanced prostate cancer

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel Deaconess Medical Center.

10 Mar 2026

Boron neutron capture therapy shows promise for deadly brain tumors

Malignant gliomas are among the deadliest brain cancers, with limited treatment options and poor survival.

9 Mar 2026

Research reveals nuclear metabolic fingerprint in human cells

More than two hundred metabolic enzymes, many of which are normally tasked with producing energy in the mitochondria, are also found sitting directly on top of human DNA, according to a study published today in Nature Communications.

6 Mar 2026

DNA nanomachine strategy reverses chemoresistance in small cell lung cancer

Professor Chao Zhang's team at Zhujiang Hospital, Southern Medical University, has developed a novel DNA nanomachine-based drug delivery and release strategy aimed at overcoming chemoresistance in small cell lung cancer (SCLC).

6 Mar 2026

A review of methionine dependency in modern cancer therapy

Methionine restriction (MR) has shown significant promise in cancer therapy because it targets the unique methionine dependency of many tumors. However, despite extensive research on MR, a clear synthesis of preclinical findings and their translation into clinical settings is lacking. This review aims to address this gap by consolidating existing evidence, identifying challenges, and highlighting opportunities for advancing MR as a viable cancer treatment strategy.

6 Mar 2026

Dual targeting strategy may improve treatment for resistant lung cancers

Findings from a study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) support the potential of new therapies that could improve clinical outcomes for patients with squamous and adenocarcinoma non-small cell lung cancers (NSCLC) that don't respond to immunotherapy.

5 Mar 2026